RETROSPECTIVE VISION OF LUNG CANCER IN ECUADOR

Leonardo David Villacres; Gabriela Claudio; Paola Claudio Pombosa; Juan Jose Navarrete; Daysi Leon; Marco Leon Montenegro; Tannia Soria

Volume : VIII, Issue : I, January - 2019

RETROSPECTIVE VISION OF LUNG CANCER IN ECUADOR

Leonardo David Villacres, Gabriela Claudio, Paola Claudio Pombosa, Juan Jose Navarrete, Daysi Leon, Marco Leon Montenegro, Tannia Soria

Abstract :

OBJECTIVE.– Retrospective analysis of patients survival with non–small cell lung cancer who received Paclitaxel / Carboplatin chemotherapy. METHODS.– Patients older than 18 years old with a diagnosis of non–small cell lung adenocarcinoma, clinical stage IV or early clinical in progression; without knowledge in relation to mutation of EGFR and reordering of ALK, during the years 2010–2016. RESULTS.– there is no stadistic difference in patients younger than 60 years old and older than 60 years old with p = 0.54. There is no statistical difference in survival in patients who consumed tobacco with p = 0.2. Patients who received Paclitaxel / Carboplatin chemotherapy have an average survival of 11.10 months, HR: 1.26 IC95% (8.67–13.62) CONCLUSION.– In Ecuador, in 2018, we continued using Paclitaxel / Carboplatin chemotherapy as a first line of treatment in metastatic lung adenocarcinoma +/– Bevacizumab; state policies should be changed and ways to improve this problem should be sought even more with the medical advances in lung cancer with specific drivers as the use of tyrosine kinase inhibitors and immunotherapy and thus improve the average survival of this population group.